Search

Displaying results 3261 - 3270 of 7540 in total
  1. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector

  2. Drug

    Flumethasone

    go.drugbank.com/drugs/DB00663
    ApprovedVet approved

    This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching.

  3. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent … T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis.

  4. Drug

    Edrophonium

    go.drugbank.com/drugs/DB01010
    Approved

    It has also been used as an antidote to curare principles.

    Synonyms: 3-hydroxy-N,N-dimethyl-N-ethylanilinium, N-ethyl-3-hydroxy-N,N-dimethylanilinium
  5. Drug

    Temocapril

    go.drugbank.com/drugs/DB08836
    Investigational

    Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea.

    Categories: Agents Acting on the Renin-Angiotensin System
  6. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    [A254222] Plasmepsins are aspartyl proteases produced by the malaria parasite _Plasmodium falciparum_, and PMX is considered to be essential for parasite egress and invasion. … It has shown high potency in biochemical (IC<sub>50</sub> = 7 nM), _in vitro_ (_P. falciparum_ 3D7 lactate dehydrogenase growth inhibition assay IC<sub>50</sub> = 10 nM), and _in vivo_ (50 mg/kg dose

  7. Drug

    Tranylcypromine

    go.drugbank.com/drugs/DB00752
    ApprovedInvestigational

    Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring.

    Categories: Monoamine Oxidase Inhibitors, Non-Selective, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Reglitazar

    go.drugbank.com/drugs/DB04971
    Experimental

    Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.

  9. Drug

    Sinecatechins

    go.drugbank.com/drugs/DB01266
    ApprovedInvestigationalNutraceutical

    Catechins constitute 85 to 95% (by weight) of the total drug substance which includes more than 55% of Epigallocatechin gallate (EGCg), other catechin derivatives such as Epicatechin (EC), Epigallocatechin … In addition to the known catechin components, it also contains gallic acid, caffeine, and theobromine which together constitute about 2.5% of the drug substance.

  10. Drug

    Oportuzumab monatox

    go.drugbank.com/drugs/DB05319
    Investigational

    VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. … VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of epithelial origin